menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    FDA Confirms Para IV Patent Litigation for Dyanavel XR Tablets

    FDA

    Enforcement Report - Week of November 27, 2024

    FDA

    Lupin receives FDA approval for generic version of Adderall XR

    EXPRESSPHARMA

    US charges executives at ADHD startup in Adderall fraud

    REUTERS

    Enforcement Report - Week of February 7, 2024

    FDA

    Drug mix-up prompts Azurity to recall 1 lot of Zenzedi

    FIERCE PHARMA

    Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing

    FDA

    Lawmakers push FDA, DEA for update amid Adderall shortage

    FIERCE PHARMA

    Glenmark and Cediprof announce exclusive distribution agreement in US

    ECONOMIC TIMES

    Granules Pharma Receives ANDA Approval for Amphetamine Mixed Salts ER Capsules

    PRESS RELEASE

    Granules gets USFDA`s nod for Amphetamine capsules

    ECONOMIC TIMES

    XELSTRYM transdermal system, CII, to be revealed as available soon at APSARD

    PR NEWSWIRE

    FDA`s drug shortages leader wants companies to start reporting increases

    ENDPTS

    Tris Pharma Announces Continued Supply and Availability of DYANAVEL Tablets

    PRNEWSWIRE

    Enforcement Report - Week of September 21, 2022

    FDA

    Tris`s Generic Dextroamphetamine Sulfate Receives Approval in the U.S.

    FDA

    Tris Pharma Announces Availability of New DYANAVEL XR Tablets for ADHD

    PRNEWSWIRE

    Teva runs into Adderall supply hitch as ADHD diagnoses mount

    FIERCEPHARMA

    Tris Pharma Announces Publication of Study Results of DYANAVEL XR in ADHD

    PRNEWSWIRE

    FDA warns websites illegally selling ADHD drug Adderall

    REUTERS

    FDA warns websites illegally selling ADHD drug Adderall

    REUTERS

    Vallon`s abuse-resistant Adderall fails clinical trial; stocks plunge 70%

    BIZJOURNALS

    Granules Pharma receives ANDA approval for Amphetamine mixed salts from US FDA

    EXPRESS PHARMA

    ADHD drug developer Cingulate sets terms for $50 million IPO

    RENAISSANCECAPITAL

    Rhodes Pharms`s Generic Amphetamine Sulphate Receives Approval in the US

    FDA

    Winder Labs Llc`s Generic Dextroamphetamine Sulfate Receives Approval In US

    FDA

    Noven to Present Pivotal Study Results for Investigational Dextroamphetamine

    BUSINESSWIRE

    Ascent`s Generic Amphetamine ; Dextroamphetamine Receives Approval In US

    FDA

    Noven Submits New Drug Application for Investigational Dextroamphetamine

    BUSINESSWIRE

    RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE

    GLOBENEWSWIRE

    Glenmark Pharmaceuticals`s Generic Amphetamine Sulfate Receives Approval In US

    FDA

    Sun Pharm`s Generic Amphetamine Sulfate Receives Approval In US

    FDA

    RECORDATI RARE DISEASES: CARBAGLU® 200mg Receives U.S. FDA Approval

    PRNEWSWIRE

    Tris Pharma Presents Positive Results from Phase 3 Study of Amphetamine

    PRNEWSWIRE

    Tris Pharma to Debut Amphetamine Extended-Release Tablet Efficacy

    PRNEWSWIRE

    Tris Pharma to Present Amphetamine Extended-Release Tablet Data

    PRNEWSWIRE

    Tris Pharma to Present Amphetamine Extended-Release Tablet Data

    PRNEWSWIRE

    Riconpharma`s Generic Amphetamine Sulfate Receives Approval in US

    FDA

    Recordati: Positive Results From the PH III LINC-3 Study of Isturisa®

    BUSINESSWIRE

    Mayne Pharma’s Generic Amphetamine Sulfate Receives Approval In US

    FDA

    Enforcement Report - Week of June 10, 2020

    FDA

    Recordati Rare Diseases Announces First European Launch of Isturisa®

    BUSINESSWIRE

    Havix`s Generic Amphetamine Sulfate Receives Approval In US

    FDA

    Recordati Rare Diseases Inc. Announces Availability of ISTURISA®

    BUSINESSWIRE

    Dr. Reddy`s Laboratories announces the launch of Amphetamine Sulfate Tablets

    BUSINESSWIRE

    Recordati Rare Diseases now holds Isturisa® European MA

    GLOBENEWSWIRE

    Prinston Inc Generic Amphetamine Sulfate Receives Approval in US

    FDA

    Cerovene`s Generic Amphetamine sulphate Receives Approval in US

    FDA

    Sungen Pharma`s generic Amphetamine Aspartate;Amphetamine Sulfate Receives Approval in US

    FDA

    Enforcement Report - Week of October 23, 2019

    FDA

    French weight-loss pill scandal set for landmark trial

    REUTERS

    FDA Consults on Abuse-Deterrent CNS Stimulants

    RAPS

    Granules Pharm`s Generic Amphetamine sulphate Receives Approval In US

    FDA

    USFDA nod for Granules’ ANDA

    THEHINDU

    Nesher Pharms` Generic Amphetamine Aspartate;Amphetamine Sulfate;Dextroamphetamine Saccharate;Dextroamphetamine Sulfate Receives Approval In US

    FDA

    SPECGX LLC Generic AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE Receives Tentative Approval In US

    FDA

    Sun Pharms Generic Amphetamine Aspartate :Amphetamine Sulfate: Dextroamphetamine Saccharate:Dextroamphetamine Sulfate Receives Approval in US

    FDA

    Lannett Company launches generic Adderall

    PHARMABIZ

    FDA Drafts Guidance for Developing Drugs to Treat ADHD

    RAPS

    Specgx LLC Generic Amphetamine Aspartate; Amphetamine Sulfate;Dextroamphetamine Saccharate;Dextroamphetamine Sulfat Receives Approval in US

    FDA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.